Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models-Reference-Cited by-同舟云学术

Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models

Published:2021-05-03 Issue:11 Volume:25 Page:4950-4961
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cell Mol Med

Author:

Grojean Meghan¹,Schwarz Margaret A.²³,Schwarz Johann R.¹,Hassan Sazzad¹³,von Holzen Urz¹³⁴⁵,Zhang Changhua⁶,Schwarz Roderich E.¹³⁷⁸,Awasthi Niranjan¹³^ORCID

Affiliation:

1. Department of Surgery Indiana University School of Medicine South Bend IN USA

2. Department of Pediatrics Indiana University School of Medicine South Bend IN USA

3. Harper Cancer Research Institute University of Notre Dame South Bend IN USA

4. Goshen Center for Cancer Care Goshen IN USA

5. University of Basel Basel Switzerland

6. Department of Gastrointestinal Surgery The Seventh Affiliated Hospital of Sun Yat‐sen University Shenzhen China

7. Roswell Park Comprehensive Cancer Center Buffalo NY USA

8. University of Buffalo Buffalo NY USA

Funder

School of Medicine, Indiana University

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.16362

Reference54 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

3. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

4. Phase II Study of Low-Dose Docetaxel/Fluorouracil/Cisplatin in Metastatic Gastric Carcinoma

5. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DRN-CDR: A cancer drug response prediction model using multi-omics and drug features;Computational Biology and Chemistry;2024-10

2. Research progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review;World Journal of Gastrointestinal Oncology;2024-08-15

3. Redefining the significance of quinoline containing compounds as potent VEGFR-2 inhibitors for cancer therapy;Medicinal Chemistry Research;2024-06-27

4. Ferroptosis regulating lipid peroxidation metabolism in the occurrence and development of gastric cancer;World Journal of Gastrointestinal Oncology;2024-06-15

5. A novel PH1/pE27HGFK1 nanoparticles for orthotopic glioblastoma therapy;Cancer Nanotechnology;2024-06-13